--- title: "Ethos Tech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286606947.md" datetime: "2026-05-15T20:05:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286606947.md) - [en](https://longbridge.com/en/news/286606947.md) - [zh-HK](https://longbridge.com/zh-HK/news/286606947.md) --- # Ethos Tech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0, missing the estimate of USD 145.02 M. EPS: As of FY2026 Q1, the actual value is USD -0.11, beating the estimate of USD -2.6542. EBIT: As of FY2026 Q1, the actual value is USD -12.08 M. Ethos Technologies Inc. operates as a single segment, focusing on the discovery and development of product candidates. #### Consolidated Net Loss For the three months ended March 31, 2026, Ethos Technologies Inc. reported a consolidated net loss of - $10.792 million, an improvement from a net loss of - $14.881 million for the three months ended March 31, 2025. #### Operating Expenses Research and Development (R&D) expenses decreased by $4.497 million, from $11.814 million in the three months ended March 31, 2025, to $7.317 million in the same period of 2026. Efzofitimod expenses decreased to $3.535 million in 2026 from $8.804 million in 2025, primarily due to the completion of the EFZO-FIT study and decreased manufacturing costs. Preclinical development and other shared R&D expenses increased to $3.355 million in 2026 from $2.560 million in 2025, mainly due to increased discovery costs for preclinical product candidates. Non-cash R&D expenses were $427 thousand in 2026, consistent with $450 thousand in 2025. General and Administrative (G&A) expenses increased by $0.160 million, from $3.959 million in the three months ended March 31, 2025, to $4.119 million in the same period of 2026. Other G&A expenses remained consistent, at $3.076 million in 2026 compared to $3.064 million in 2025. Non-cash G&A expenses increased to $1.043 million in 2026 from $895 thousand in 2025, primarily due to increased stock-based compensation. #### Other Income (Expense), Net Other income (expense), net, was $0.644 million for the three months ended March 31, 2026, down from $0.892 million in the prior year, primarily due to lower interest rates and lower interest earned on reduced cash balances. #### Cash Flow from Operating Activities Net cash used in operating activities was - $12.517 million for the three months ended March 31, 2026, compared to - $15.420 million for the same period in 2025. #### Cash Flow from Investing Activities Net cash provided by investing activities was $11.494 million for the three months ended March 31, 2026, a significant change from net cash used of - $4.420 million in the same period of 2025, primarily due to timing differences in investment purchases, sales, and maturities. #### Cash Flow from Financing Activities Net cash used in financing activities was - $0.142 million for the three months ended March 31, 2026, compared to net cash provided of $18.628 million in the same period of 2025, which included $18.8 million in proceeds from stock issuance through the Jefferies ATM Offering Program. #### Liquidity and Capital Resources As of March 31, 2026, Ethos Technologies Inc. had cash, cash equivalents, restricted cash, and available-for-sale investments totaling $68.3 million, and an accumulated deficit of $617.0 million. The company believes these resources will be sufficient to meet material cash requirements for at least one year from the filing date. #### Future Outlook and Strategy Ethos Technologies Inc. plans to continue the development of efzofitimod in pulmonary sarcoidosis with a planned Phase 3 study, using FVC as the primary endpoint and KSQ-Lung score as the key secondary endpoint, targeting patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company intends to increase the dosing frequency to once every three weeks and submit an investigational new drug (IND) application for this study in June 2026. The Kyorin Agreement was terminated on May 12, 2026, resulting in Ethos Technologies Inc. not receiving future milestone payments, including $155.0 million in aggregate, or tiered royalties from Japan, but regaining global development and commercialization rights for efzofitimod. ### Related Stocks - [LIFE.US](https://longbridge.com/en/quote/LIFE.US.md) ## Related News & Research - [PowerFleet Q4 2026 Earnings Preview](https://longbridge.com/en/news/289616465.md) - [ABB Ltd: ABB share buybacks - June 4, 2026 – June 10, 2026](https://longbridge.com/en/news/289436946.md) - [Soybean Analysis: 2026 Market Volatility and Trend](https://longbridge.com/en/news/289444628.md) - [Zedge Q3 2026 Earnings Preview](https://longbridge.com/en/news/289381005.md) - [3 High-Yield (7%+) Bond ETFs for Income-Seeking Investors to Buy in 2026](https://longbridge.com/en/news/289655624.md)